MediciNova believes the appropriate clinical development for MN-221 will involve conducting dose regimen and AEA trial design optimization studies prior to commencing pivotal trials. Currently, MediciNova is working with licensor and API supplier, Kissei Pharmaceutical Co., Ltd. to address the manufacturing requirements before further clinical development is commenced. MediciNova has determined that any additional future MN-221 clinical trial development will be partner-dependent from a funding perspective."We believe the recently-allowed patent for MN-221 for use in the treatment of AEA can significantly increase the length of marketing exclusivity and hence the potential value of MN-221," said Dr. Kazuko Matsuda, patent inventor and Chief Medical Officer of MediciNova. "We look forward to keeping our shareholders updated on our MN-221 progress."
MediciNova Provides Development Update
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts